Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 1, 2006, Pages 10-13

  Huisman, M V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BACTERIAL COLONIZATION; BLEEDING; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CATHETER; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SCREENING TEST; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM; VULNERABLE POPULATION; CENTRAL VENOUS CATHETERIZATION; NEOPLASM; PREMEDICATION; TREATMENT OUTCOME;

CATHETERIZATION, CENTRAL VENOUS; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES; PREMEDICATION; THROMBOSIS; TREATMENT OUTCOME;

EID: 33644859104     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01735.x     Document Type: Article

References (30)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism. Chest 2004; 126: 338S-400S.
2. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complication and failure of subclavian-vein catheterization. N Engl J Med 1994; 331: 1735-8.
3. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999; 25: 147-55.
4. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-75.
5. De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D, Morassut S, Testa V. Central venous thrombosis: An early and frequent complication in cancer patients bearing long term silastic catheter -a prospective study. Thromb Res 1997; 86: 101-13.
6. Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A. Upper extremity deep venous thrombosis and pulmonary embolism: A prospective study. Chest 1991; 99: 280-3.
7. Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, Llamazares JF. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines: A prospective study. Thromb Haemost 1994; 72: 548-50.
8. Klerk CPW, Smorenburg SM, Buller HR. Thrombosis prophylaxis in patient populations with a central venous catheter. Arch Int Med 2003; 163: 1913-21.
9. Bern MM, Lokich JJ, Wallach SR, Bothe Jr A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial. Ann Intern Med 1990; 112: 423-8.
10. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed mini-dose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987; 295: 1309-12.
11. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med 2002; 32: 84-8.
12. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063-9.
13. Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, Pedicini V, Fallini M, Santoro A. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy ? J Clin Oncol 2003; 21: 736-9.
14. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices: Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-3.
15. Reichardt P, Kretzschmar A, Biakhov M. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight-heparin (dalteparin sodium) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs). Proc Am Soc Clin Oncol 2002; 21: 369a (Abstr 1474).
16. Abdelkefi A, Ben Othman T, Kammoun L, Chelli M, Romdhane NB, Kriaa A, Ladeb S, Torjman L, Lakhal A, Achour W, Ben Hassen A, Hsairi M, Ladeb F, Ben Abdeladhim A. Prevention of central venous line related thrombosis by continuous infusion of low dose unfractionated heparin in patients with hemato-oncological disease. Thromb Haemost 2004; 92: 654-61.
17. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Soraru M, Mosca S. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-62.
18. Levine M, Kakkar AK. Catheter-associated thrombosis: Thromboprophylaxis or not ? J Clin Oncol 2005; 23: 4006-4008
19. Hull RD, Pineo GF, Stein PD. Extended out of hospital low molecular weight heparin prophylaxis against deep vein thrombosis in patients after hip arthroplasty. Ann Int Med 2001; 135: 858-69.
20. Mandala M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A, Factor V. Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15: 590-3.
21. Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89: 201-6.
22. Jansen FH, van der Straaten HM, Roest M, Haas F, de Groot PG, Fijnheer R. Elevated levels of D-dimer and fragment 1&2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica 2005; 90: 499-504.
23. Abdelkefi A, Ben Romdhane N, Kriaa A. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant 2005; 36: 885-9.
24. Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S. Risk factors for thrombosis in cancer patients. Eur J Cancer 2004; 40: 2253-9.
25. Van Rooden CJ, Monraats PS, Kettenis IM. Low physician compliance of prescribing anticoagulant prophylaxis in patients with solid tumor or hematological malignancies and central vein catheters. J Thromb Haemost 2003; 1: 1842-3.
26. van Rooden CJ, Rosendaal FR, Barge RM, van Oostayen JA, van der Meer FJ, Meinders AE, Huisman MV. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol 2003; 123: 507-12.
27. Jansen FH, van der Straaten HM, Roest M, Haas F, de Groot PG, Fijnheer R. Elevated levels of D-dimer and fragment 1 + 2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica 2005; 90: 499-504.
28. Hoch JR. Management of the complications of long-term venous access. Semin Vasc Surg 1997; 10: 135-43.
29. Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271: 1014-6.
30. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters; a meta-analysis of randomised controlled trials. Chest 1998; 113: 165-71.